Regen Peptide Stack: BPC-157, TB-500, Epitalon, and GHRP Protocols Explained

What Exactly Is the Regen Peptide Stack?

The regen peptide stack is a multi-agent protocol that pairs two tissue-repair peptides (BPC-157 and TB-500), one telomere-support peptide (epitalon or its N-acetyl form), and one growth hormone secretagogue (GHRP-2 or GHRP-6) into a single coordinated regimen. The four agents target different receptor systems simultaneously. BPC-157 works through vascular endothelial growth factor (VEGF) and the nitric-oxide (NO) pathway [1]; TB-500 sequesters G-actin to mobilize progenitor cells [2]; epitalon activates telomerase reverse transcriptase [3]; and the GHRPs bind ghrelin receptors (GHS-R1a) to pulse growth hormone release [4].

Stacking these peptides is not about doubling a single effect. Each pathway is mechanistically independent, which is why pre-clinical and early clinical data suggest additive outcomes rather than simple redundancy. A 2023 review in the International Journal of Molecular Sciences noted that BPC-157 and thymosin beta-4 (the parent molecule of TB-500's active fragment) act on overlapping but non-identical angiogenic targets, providing complementary support for wound repair [1].

Physicians at HealthRX structure this stack in cycles of 8 to 12 weeks, with a mandatory washout of at least 4 weeks between cycles, to minimize receptor desensitization and to allow baseline labs to be re-evaluated.

BPC-157 Fragments: Which Fragment Matters and Why

BPC-157 is a 15-amino-acid synthetic peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a gastric mucosal protein. The "fragment" designation refers to the fact that BPC-157 itself is already a fragment of the full-length body protection compound; some compounders further abbreviate the sequence to a stable hexapeptide core for oral formulation.

The most studied form remains the full 15-mer. Animal studies demonstrate consistent acceleration of tendon-to-bone healing, with one rat model showing complete transected Achilles tendon repair at 14 days versus partial repair in controls (P<0.01) [5]. A separate rodent study published in the Journal of Physiology and Pharmacology found that BPC-157 at 10 mcg/kg/day significantly reduced gastric ulcer area by 78% versus vehicle control [6]. Human data are limited to a handful of case reports and one small open-label pilot, so the mechanistic picture still outpaces clinical trial evidence.

Subcutaneous injection at 250 to 500 mcg once or twice daily is the most common physician-supervised protocol. Site-specific intramuscular injection adjacent to a target tissue (for example, peri-tendinous injection near the Achilles) is used by some clinicians to concentrate local effect, though no randomized controlled trial has compared systemic versus local delivery in humans [5].

Oral BPC-157 formulations use an arginine salt (BPC-157 arginate) to survive stomach acid. Pre-clinical data show systemic bioavailability via the oral route, but absorption percentage is lower than subcutaneous delivery [6].

TB-500 Fragments: Ac-SDKP and the Thymosin Beta-4 Connection

TB-500 is the synthetic version of thymosin beta-4 (Tβ4), a 43-amino-acid ubiquitous actin-sequestering peptide. The "fragment" most cited in research is Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), a tetrapeptide naturally released from Tβ4 by prolyl oligopeptidase. Ac-SDKP independently inhibits cardiac and renal fibrosis and suppresses TGF-beta1-driven myofibroblast differentiation [2].

Full-length TB-500 (the complete Tβ4 sequence) binds G-actin through its LKKTETQ motif, lowering the critical concentration needed for filament assembly and thereby accelerating lamellipodia formation in migrating repair cells [2]. A 2010 study in Annals of the New York Academy of Sciences documented that Tβ4 improved cardiac function in a mouse myocardial infarction model, reducing infarct size by roughly 25% at 28 days [7]. A later study in Journal of the American College of Cardiology found Tβ4 promoted epicardial progenitor cell activation after cardiac injury [8].

In the regen stack, TB-500 is typically dosed at 2 to 2.5 mg subcutaneously twice per week for a loading phase of 4 to 6 weeks, then reduced to a maintenance dose of 1 to 2 mg once or twice monthly. This loading-then-maintenance structure mirrors the dosing used in the veterinary literature, where TB-500 is more extensively studied in equine musculoskeletal injury [9].

The Ac-SDKP fragment alone is available from some compounders as a targeted anti-fibrotic option. Physicians may prefer it when the primary goal is renal or cardiac tissue preservation rather than broad musculoskeletal repair, because its anti-fibrotic effect on TGF-beta1 is more potent per microgram than full-length Tβ4 [2].

N-Acetyl Epitalon: Mechanism, Dosing, and What the Trials Show

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the pineal peptide epithalamin. The N-acetyl form (N-acetyl epitalon) was developed to improve stability and membrane permeability. Its primary mechanism is stimulation of telomerase reverse transcriptase (TERT), the enzyme that elongates telomeres in somatic cells [3].

The most cited human trial is a 2003 study by Khavinson et al. published in the Bulletin of Experimental Biology and Medicine, which found that epitalon administered to elderly volunteers over 2 years produced statistically significant lengthening of telomere length in peripheral blood lymphocytes compared with controls (P<0.05) [3]. A separate 12-year mortality follow-up study in elderly patients treated with epithalamin (the pineal extract precursor to epitalon) reported a 28% reduction in mortality and a 36% reduction in cardiovascular mortality versus controls [10].

Epitalon also modulates the pineal gland's melatonin secretion. Rodent studies show it normalizes age-related decline in nocturnal melatonin peaks [10]. This melatonin-restoration effect is thought to be secondary to telomerase activation in pinealocytes rather than direct hormone replacement.

Clinical dosing in supervised protocols is 10 mg subcutaneously, administered nightly for 10, 20 consecutive nights, once or twice per year. The N-acetyl modification extends half-life slightly and may reduce injection-site irritation, which is why it is preferred over unmodified epitalon in compounded formulations [3].

Telomere length testing (e.g., Life Length or Repeat Diagnostics platforms) before and after a cycle provides an objective biomarker for response, though the clinical relevance of a measurable telomere-length increase in terms of long-term disease endpoints has not been established in prospective controlled trials.

GHRP-2 vs GHRP-6: Choosing the Right Secretagogue for the Regen Stack

Both GHRP-2 and GHRP-6 are synthetic hexapeptides that bind the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary, triggering a pulsatile release of endogenous growth hormone [4]. The choice between them shapes the metabolic and appetite profile of the entire stack.

GHRP-2 (also called pralmorelin) produces a stronger, cleaner GH pulse. A crossover study in 10 healthy men found that 1 mcg/kg intravenous GHRP-2 produced a mean peak GH of 53.9 ng/mL, compared with 35.2 ng/mL for an equivalent GHRP-6 dose [4]. GHRP-2 causes modest cortisol and prolactin co-secretion but minimal appetite stimulation, making it the preferred choice for patients who already have adequate caloric intake or who are managing body composition goals [11].

GHRP-6 produces a lower but sustained GH pulse and causes pronounced ghrelin-mediated appetite stimulation, often increasing hunger within 20 to 30 minutes of injection [11]. This makes GHRP-6 appropriate for patients in catabolic states, post-surgical recovery, or those with poor appetite secondary to illness or aging. The appetite effect, while unwanted for some, can be a clinical tool for others.

Standard dosing for both peptides is 100 to 300 mcg subcutaneously, administered two to three times daily in a fasted state (at least 90 minutes post-meal and 30 minutes pre-meal) to avoid blunting of the GH pulse by somatostatin-suppressing insulin [12]. When combined with a GHRH analog (e.g., CJC-1295 without DAC or modified GRF 1-29), GH output roughly doubles due to synergistic receptor activation at the somatotroph [12].

In the regen stack, the GHRP component supports the repair peptides by driving IGF-1 production, which amplifies collagen synthesis and satellite cell activation in muscle tissue. A 2019 study in Growth Hormone and IGF Research confirmed that pulsatile GH secretion, as opposed to constant GH infusion, more effectively preserves IGF-1 receptor sensitivity over 12 weeks [13].

How These Four Peptides Work Together: The Regen Stack Mechanism Map

The regen stack functions across four mechanistic layers simultaneously.

At the vascular layer, BPC-157 upregulates VEGF-A expression and eNOS activity, accelerating capillary ingrowth into ischemic or damaged tissue within 3 to 5 days of initiation in rodent models [1]. Without adequate blood supply, the cellular repair promoted by TB-500 cannot be sustained.

At the cellular migration layer, TB-500 (via its LKKTETQ actin-binding domain) lowers the threshold for lamellipodia extension in fibroblasts and endothelial progenitor cells, allowing them to reach the injury site 30 to 40% faster in animal wound models [2].

At the genomic maintenance layer, N-acetyl epitalon prevents the progressive telomere shortening that limits the replicative capacity of repair cells. Cells with critically short telomeres enter senescence and stop dividing; epitalon's TERT stimulation extends the window during which these cells can continue proliferating to fill a repair zone [3].

At the anabolic signaling layer, the chosen GHRP pulses GH, which drives hepatic IGF-1 synthesis. IGF-1 then binds receptors on fibroblasts, myocytes, and chondrocytes to accelerate extracellular matrix deposition and cell division [13]. This layer amplifies the tissue-building output of the first three mechanisms.

Dosing Schedule: A Practical 12-Week Regen Protocol

The schedule below reflects common physician-supervised practice. Individual adjustments based on labs, body weight, and treatment goals are required.

Weeks 1, 4 (Loading Phase): BPC-157 500 mcg subcutaneous twice daily, AM and PM. TB-500 2.5 mg subcutaneous twice weekly (e.g., Monday and Thursday). GHRP-2 200 mcg subcutaneous three times daily (fasted: upon waking, early afternoon, and before bed). N-acetyl epitalon 10 mg subcutaneous nightly for the first 14 nights of this phase, then discontinued until the next cycle.

Weeks 5, 12 (Maintenance Phase): BPC-157 250 mcg subcutaneous once daily. TB-500 2 mg subcutaneous once monthly. GHRP-2 200 mcg subcutaneous twice daily (upon waking and before bed).

Baseline labs before starting: IGF-1, fasting insulin, fasting glucose, comprehensive metabolic panel, CBC, and C-reactive protein. Repeat IGF-1 and CRP at week 6. If IGF-1 exceeds 350 ng/mL, reduce GHRP frequency to twice daily from three times daily.

Safety Profile, Side Effects, and Contraindications

No randomized placebo-controlled trial in humans has evaluated the full four-peptide regen stack as a combined protocol. Each agent carries its own risk profile derived from pre-clinical data and limited human use.

BPC-157 has not shown organ toxicity in rodent studies at doses up to 100 times the standard human equivalent [5]. The most common reported side effect in clinical practice is mild injection-site redness, lasting under 24 hours [6].

TB-500 at therapeutic doses has not produced documented adverse events in the veterinary literature over 15 years of use in equine practice [9]. Theoretical concern exists for promoting growth of occult malignancies, given that VEGF and actin-mediated cell migration are also features of tumor angiogenesis. Patients with a personal or first-degree family history of cancer should discuss this risk explicitly with their prescribing physician before proceeding [7].

Epitalon's 12-year follow-up data showed no increased cancer incidence and a reduced all-cause mortality signal [10], though this was an observational study in a Soviet-era cohort and carries significant methodological limitations.

GHRP-2 and GHRP-6 raise cortisol and prolactin transiently at supra-physiologic doses above 300 mcg per injection [11]. Patients with diabetes or pre-diabetes should monitor fasting glucose more frequently because GH is a counter-regulatory hormone that can worsen insulin sensitivity [12].

Absolute contraindications for all four peptides include active malignancy, pregnancy, and breastfeeding. Relative contraindications include proliferative diabetic retinopathy, untreated acromegaly, and current corticosteroid therapy above physiologic replacement doses.

Lab Monitoring Framework for the Regen Stack

Monitoring at set intervals reduces guesswork and provides the legal and clinical documentation required for compounded peptide protocols.

Before starting: IGF-1 (target range 150 to 300 ng/mL for adults over 40), fasting glucose, HbA1c, CRP (high-sensitivity), CBC with differential, comprehensive metabolic panel. Baseline telomere length testing is optional but recommended when epitalon is included.

At week 6: IGF-1, fasting glucose, CRP. Adjust GHRP dose if IGF-1 is above 350 ng/mL.

At week 12 (end of cycle): Full repeat of baseline panel plus prolactin. A washout of 4 to 6 weeks before the next cycle allows IGF-1 to return to baseline and confirms that GH-axis feedback has reset [13].

Patients on concurrent testosterone replacement therapy should note that testosterone amplifies GH pulse amplitude by approximately 20% [14], which may require downward adjustment of GHRP dose to keep IGF-1 within the target window.

Regulatory and Legal Status in the United States

None of the four peptides in the regen stack are FDA-approved drugs for human use in any indication. BPC-157 and TB-500 were placed on the FDA's list of substances that may not be compounded under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act in a 2023 guidance document [15]. N-acetyl epitalon and the GHRPs occupy a gray zone: they are not on the prohibited compounding list but are also not FDA-approved, meaning their use is strictly research-context or off-label through physician prescription.

The legal exposure rests with both the prescribing physician and the patient. Sourcing from an unaccredited compounding pharmacy or an online "research chemicals" vendor eliminates physician oversight and quality control. Sterility testing, endotoxin testing, and certificate of analysis verification are non-negotiable when peptides are administered by injection [15].

The FDA's 2023 guidance does not prohibit a physician from prescribing these compounds; it prohibits their preparation by licensed compounding pharmacies under the 503A/B safe-harbor provision. Physicians operating within IRB-approved research protocols may still administer these agents [15].